KBC Securities - Hyloris Pharmaceuticals (HYL) Morning Notes : HYL BB

Report

KBC Securities

Hilde Van Boxstael ...

Jacob Mekhael
Thomas Couvreur

Morning Notes : HYL BB

: HYL BB

31/03/2025 1 EN

Underlying

Hyloris Pharmaceuticals

See profile

BE0974363955 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Hilde Van Boxstael

Jacob Mekhael

Thomas Couvreur

Other Reports on these Companies

KBC Securities

Hyloris FIRST LOOK: Collaboration with AFT to develop HY-094 for iron deficiency

Hyloris entered into a late-stage research and development program in collaboration with AFT to introduce an injectable iron deficiency therapy (HY-094) to the global market – development costs and net margin from sales and licensing will be distributed equally. This announcement brings a new later stage product to the company's pipeline, for which Hyloris expects phase 3 development to start in the near-term. Given the size of the market, we expect this will be a high volume product and Hyloris will need to find a commercialisation partner with a large footprint. We note that Hyloris previous...

March 31, 2025 March 31, 2025 1 EN

KBC Securities

Hyloris FIRST LOOK: FY24 results come with a detailed pipeline update

Hyloris reported FY24 results with YE24 cash of € 23.6m (YE23: € 30.4m). Revenue grew to € 8.5m (from € 2.1m), though we note this included one-off milestone payments ($ 2.1m as well as an additional undisclosed amount). We are encouraged by the planned 9 regulatory submissions by YE26, though point out that US filing fees range $ 2-4m. Additionally, Hyloris will require extra funding to commercialise the near-term cardiology products in the US and is exploring multiple options. As such, while we acknowledge the company's operational progress, we'll look to see how Hyloris' funding plans evolv...

March 21, 2025 March 21, 2025 1 EN

MaaT Pharma To present preclinical data on MaaT034 at AACR

MaaT will present new non-clinical data on MaaT034 (donor independent microbiome therapy) at the American Association for Cancer Research (AACR) conference, taking place on 25-30 April. The results demonstrate MaaT034's potential as a combination therapy to improve responses to checkpoint inhibitors in solid tumours. Being co-cultured means MaaT034 is donor-independent, which offers the scale required for the larger solid tumour market. Initial data from the phase 2 placebo-controlled trial of lead product MaaT013 (donor dependent) in combination with checkpoint inhibitors in metastatic melano...

19h / 40m 19h / 40m 1 EN

Guy Sips ... (+4)

Guy Sips
Jacob Mekhael
Thomas Vranken
Wim Hoste

Morning Notes : COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

: COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

19h / 44m 19h / 44m 1 EN

Thomas Vranken

Thomas Vranken

Onward Medical 2024 was a transformational year, 2025 to scale commercialization

Onward reported its FY24 business update, which underlined a lot of progress yet no major new surprises, and it reaffirms its outlook of main catalysts. Mgmt. confirmed demand is strong, but no commercial outlook was given yet. We look forward to an FDA label expansion for home use in 2025, while we also expect the pivotal Empower BP trial in blood pressure control to kick off. FY24 topline (€ 1.7m) and net result (€ -35.7m) came in line with our expectations, and with a € 60m cash position we believe the company is capitalized with runway into 2H26 (KBCSe). Altogether solid progress in 2024, ...

19h / 55m 19h / 55m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : HYL BB

We are a financial services provider for several types of professional clients, each with distinct needs.

Hyloris FIRST LOOK: Collaboration with AFT to develop HY-094 for iron deficiency

Hyloris FIRST LOOK: FY24 results come with a detailed pipeline update

MaaT Pharma To present preclinical data on MaaT034 at AACR

Morning Notes : COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

Onward Medical 2024 was a transformational year, 2025 to scale commercialization

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe